MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes

Table 3

Survival analysis of miRSNPs in mTOR pathway in 134 patients with stage III small cell lung cancer.

Gene SNP	Model		5yOS	HR (95% CI)	Log-rank	HR (95% CI) (adjusted)	adjusted
VEGFA rs10434	DOM	GG (90)	37.9%	0.739 (0.424–1.288)	0.284	0.830 (0.468–1.472)	0.523	0.584
		GA + AA (44)	39.6%
DDIT4 rs1053639	DOM	AA (80)	35.1%	1.042 (0.622–1.744)	0.877	0.970 (0.573–1.639)	0.908	0.709
		AT + TT (54)	42.1%
MAPK1 rs1063311	DOM	CC (97)	36.8%	0.694 (0.366–1.315)	0.260	0.542 (0.308–0.953)	0.101	0.219
		CT + TT (34)	41.7%
PTEN rs11202607	ADD	CC (111)	35.9%	0.607 (0.260–1.416)	0.243	0.493 (0.208–1.169)	0.108	0.225
		CT (22)	58.5%
PIK3R1 rs12755	REC	CA + CC (123)	36.2%	0.360 (0.088–1.475)	0.155	0.242 (0.058–1.010)	0.052	0.161
		AA (10)	70.0%
MTOR rs2536	ADD	TT (108)	43.1%	1.978 (1.087–3.600)	0.026	2.039 (1.117–3.720)	0.020	0.103
		TC (22)	21.2%
VEGFA rs3025039	DOM	CC (80)	42.9%	1.127 (0.666–1.908)	0.655	1.185 (0.687–2.044)	0.541	0.592
		CT + TT (52)	33.4%
PIK3R1 rs3756668	REC	GA + GG (109)	34.0%	0.362 (0.155–0.845)	0.014	0.341 (0.146–0.797)	0.013	0.103
		AA (23)	49.5%
PTEN rs701848	DOM	TT (47)	23.5%	0.885 (0.504–1.556)	0.672	0.759 (0.423–1.362)	0.356	0.488
		TC + CC (85)	40.8%

Adjusted for age, gender, Karnofsky performance score (KPS), smoking history, and Charlson comorbidity index (CCI).
miRSNPs: miRNA-related single nucleotide polymorphisms; OS: overall survival; HR: hazard ratio; CI: confidence interval.
Reference sequences: VEGFA GenBank NG_008732; DDIT4 GenBank NM_019058; MAPK1 GenBank NG_023054; PTEN GenBank NG_007466; PIK3R1 GenBank NG_012849; MTOR GenBank NG_033239.